Allworth Financial
CRVS icon

Allworth Financial’s Corvus Pharmaceuticals CRVS Stock Holding History

Allworth Financial’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.66K Buy
379
+317
+511% +$4.4K ﹤0.01% 4054
2026
Q1 		$908 Buy
62
+45
+265% +$718 ﹤0.01% 4596
2025
Q4 		$131 Buy
+17
New +$134 ﹤0.01% 4750

Other funds holding CRVS

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Allworth Financial's CRVS Position: Q2 2026 in Review

Allworth Financial increased its Corvus Pharmaceuticals (CRVS) stake by 511% in Q2 2026, buying an estimated $4.4K and bringing the position to 379 shares worth $5.66K. The position accounts for ﹤0.01% of the portfolio, ranked #4054.

Allworth Financial first reported a position in CRVS in Q4 2025 and has held it in 3 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Allworth Financial held 379 shares of Corvus Pharmaceuticals worth $5.66K as of Q2 2026.
  • Allworth Financial bought 317 Corvus Pharmaceuticals shares in Q2 2026, an estimated $4.4K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #4054 holding.
  • Allworth Financial first reported a position in Corvus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.